FibroGen, Inc (FGEN) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Gaia Shamus from LifeSci Advisors. Please go ahead. Thank you, Jonathan. Good afternoon, everyone. Thank you for joining us today to discuss FibroGen's second quarter 2025 financial and business results. I'm Gaia Shamus with LifeSci Advisors. Joining me on today's call are Fain Weddy, Chief Executive Officer, David DiLuccia, Chief Financial Officer, and Carol Gedham, Product Team Lead for FG3246, FG3180, and Roxadustat. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about FibroGen. Such statements may include, but are not limited to, collaboration with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in FibroGen's filing with the SEC, including our most recent Form 10-K and Form 10-Q. FibroGen does not undertake any obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise. The press release reporting the company's financial results and business updates and a webcast of today's conference call can be found on the investor section of FibreGen website ...